Trials / Completed
CompletedNCT04552535
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Second line (2L) afatinib | Afatinib |
| DRUG | Second line chemotherapy | Chemotherapy |
Timeline
- Start date
- 2020-05-08
- Primary completion
- 2020-05-18
- Completion
- 2020-05-18
- First posted
- 2020-09-17
- Last updated
- 2022-01-11
- Results posted
- 2021-07-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04552535. Inclusion in this directory is not an endorsement.